China’s National Healthcare Security Administration (NHSA) released its 2025 Healthcare Security Development Statistical Bulletin , revealing that Basic Medical Insurance (BMI) participation reached 1.33 billion people (coverage rate >95% ), with fund inflows totaling RMB 3,587.3 billion (USD 520 billion) against expenditures of RMB 3,000.9 billion (USD 440 billion) . The 2025 NRDL update added 114 new drugs , bringing total covered medicines to 3,253 , while DRG/DIP payment reform now covers >95% of inpatient cases and inter-provincial direct settlement surged 30.17% for outpatient visits , demonstrating sustained universal health coverage expansion and cost control efficiency .
Metric 2025 Result Change (YOY) Strategic Note BMI Participants 1.33 billion +4.06 million >95% coverage rate maintained Maternity Insurance 259.7 million +6.7 million Expanded social safety net Fund Inflows RMB 3,587.3 bn (USD 520 bn) — Sustainable revenue base Fund Expenditures RMB 3,000.9 bn (USD 440 bn) — 83.6% inflow-to-outflow ratio Maternity Benefits RMB 136 bn (USD 19.7 bn) — Direct patient support Fund Balance RMB 586.4 bn (USD 85 bn) — Reserve for future obligations
Healthcare Utilization Trends
Service Type 2025 Volume Change (YOY) Implication Outpatient Visits 7.215 billion +25.51% Shift to ambulatory care; COVID recovery; chronic disease management Inpatient Visits 278 million –3.40% DRG/DIP cost control reducing unnecessary admissions Average Inpatient Cost RMB 8,509.28 (USD 1,233) — Cost containment stable Low-Income Rural Access 246.3 million beneficiaries — Triple protection system (BMI + major illness insurance + medical assistance) Expense Reduction RMB 193.39 bn (USD 28 bn) — Catastrophic health expenditure protection
NRDL and Drug Access
Element 2025 Data Strategic Impact Total Covered Medicines 3,253 Comprehensive formulary Western Medicines 1,857 Innovation access Chinese Patent Medicines 1,396 Traditional medicine integration Prepared Slices 892 Herbal medicine standardization New Drugs Added 114 Annual innovation refresh; market access for pharma Negotiation Drug Visits >240 million High utilization of price-negotiated innovative drugs
Reform Initiative 2025 Coverage Efficiency Metric DRG/DIP Implementation >95% of planning areas Case-based payment standardization Short-Term Inpatient DRG/DIP >95% of cases Prospective payment controlling costs Inpatient Pooling Fund DRG/DIP >80% of expenditures Fund sustainability protection Five Supporting Mechanisms 100% of pooling regions Exceptional review, advance payment, feedback, negotiation, data working groups Data Transparency >95% publish biannually Accountability and provider benchmarking Cross-Province DRG/DIP All provinces initiated National payment harmonization
Initiative 2025 Achievement Market Impact Medical Service Price Guidelines 39 batches issued National price item unification Provincial Implementation Most completed 30 batches Standardized pricing across regions Dynamic Adjustment Triggers 23 provinces/cities eligible Routine price updates for provider viability 11th National Drug Procurement 55 drugs covered Continued generic price reduction 6th High-Value Consumables Procurement 12 types (drug-coated balloons, urological devices) Medical device cost containment
Fund Supervision and Anti-Fraud
Metric 2025 Result Enforcement Mechanism Total Fund Recovery RMB 34.2 bn (USD 4.96 bn) Comprehensive audit and monitoring AI Monitoring Recovery RMB 3 bn (USD 434 mn) Intelligent monitoring subsystem deployment Whistleblower Rewards RMB 1.558 mn (USD 226 k) Public reporting incentives Whistleblower Recovery RMB 2.74 bn (USD 397 mn) Citizen engagement in fraud detection
Inter-Provincial Settlement Network
Network Component 2025 Scale Growth (YOY) Designated Medical Institutions 655,800 Expanded national network Designated Hospitals 241,800 Inpatient access Designated Pharmacies 414,000 Retail access Inpatient Cross-Province Settlement 15.823 million visits +10.38% Outpatient Cross-Province Settlement 292 million visits +30.17%
Forward‑Looking Statements -Fineline Info & Tech
